SK153599A3 - Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety - Google Patents

Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety Download PDF

Info

Publication number
SK153599A3
SK153599A3 SK1535-99A SK153599A SK153599A3 SK 153599 A3 SK153599 A3 SK 153599A3 SK 153599 A SK153599 A SK 153599A SK 153599 A3 SK153599 A3 SK 153599A3
Authority
SK
Slovakia
Prior art keywords
cpg2
antibody
enzyme
cells
cell
Prior art date
Application number
SK1535-99A
Other languages
English (en)
Slovak (sk)
Inventor
Stephen Charles Emery
David Charles Blakey
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of SK153599A3 publication Critical patent/SK153599A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/802Virus-based particle
    • Y10S977/803Containing biological material in its interior
    • Y10S977/804Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SK1535-99A 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety SK153599A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds
PCT/GB1998/001294 WO1998051787A2 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety

Publications (1)

Publication Number Publication Date
SK153599A3 true SK153599A3 (en) 2000-06-12

Family

ID=10812048

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1535-99A SK153599A3 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety

Country Status (23)

Country Link
US (1) US6339070B1 (pt)
EP (1) EP0979292B1 (pt)
JP (1) JP2001526539A (pt)
KR (1) KR100508136B1 (pt)
CN (1) CN1268743C (pt)
AT (1) ATE412755T1 (pt)
AU (1) AU734915B2 (pt)
BR (1) BR9808769A (pt)
CA (1) CA2286875A1 (pt)
DE (1) DE69840165D1 (pt)
ES (1) ES2314990T3 (pt)
GB (2) GB9709421D0 (pt)
HU (1) HUP0001931A3 (pt)
IL (1) IL132348A0 (pt)
MY (1) MY140975A (pt)
NO (1) NO995475L (pt)
NZ (1) NZ500014A (pt)
PL (1) PL337007A1 (pt)
RU (1) RU2218404C2 (pt)
SK (1) SK153599A3 (pt)
TR (1) TR199902731T2 (pt)
WO (1) WO1998051787A2 (pt)
ZA (1) ZA983931B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910077D0 (en) 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19946142A1 (de) 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US7244592B2 (en) * 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2003104425A2 (en) * 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
WO2004069269A1 (en) * 2003-01-30 2004-08-19 Neurologix, Inc. Method for making a cell more susceptible for a compound by expressing the protein, on which said compound acts, in said cell
DK2382990T3 (en) 2003-04-30 2014-12-15 Univ Zuerich Methods of treating cancer by using an immunotoxin
JP4982183B2 (ja) * 2003-12-12 2012-07-25 ジェネンコー・インターナショナル・インク Cab分子
CN1964979B (zh) 2004-04-09 2011-07-27 中外制药株式会社 新颖的水溶性前药
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
US8263744B2 (en) * 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
WO2009039630A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
WO2010019257A2 (en) * 2008-08-13 2010-02-18 The Johns Hopkins University Prodrug activation in cancer cells using molecular switches
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CA2851892C (en) * 2011-10-28 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN105764925A (zh) 2013-10-02 2016-07-13 维文蒂亚生物公司 抗EpCAM抗体和使用方法
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
AU2016228755B2 (en) 2015-03-12 2020-09-10 Viventia Bio Inc. Methods of treatment for EPCAM positive bladder cancer
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
EP4127186A1 (en) 2020-03-24 2023-02-08 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
KR20230003477A (ko) 2020-03-24 2023-01-06 제너레이션 바이오 컴퍼니 비-바이러스성 dna 벡터 및 인자 ix 치료제 발현을 위한 이의 용도
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9423367D0 (en) 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
CZ195297A3 (en) * 1994-12-23 1997-12-17 Zeneca Ltd Pharmaceutical composition containing enzymatic component being specific for target cells
SK19498A3 (en) * 1995-08-16 1998-09-09 Zeneca Ltd Conjugates containing carboxypeptidase b mutated form and method and use of said conjugates
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
ATE350478T1 (de) * 1996-05-04 2007-01-15 Astrazeneca Ab Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector

Also Published As

Publication number Publication date
DE69840165D1 (de) 2008-12-11
IL132348A0 (en) 2001-03-19
ATE412755T1 (de) 2008-11-15
MY140975A (en) 2010-02-12
KR100508136B1 (ko) 2005-08-10
WO1998051787A3 (en) 1999-04-01
GB9922815D0 (en) 1999-11-24
US6339070B1 (en) 2002-01-15
CN1268743C (zh) 2006-08-09
BR9808769A (pt) 2000-08-01
EP0979292B1 (en) 2008-10-29
NO995475D0 (no) 1999-11-09
RU2218404C2 (ru) 2003-12-10
CN1255163A (zh) 2000-05-31
TR199902731T2 (xx) 2000-06-21
HUP0001931A2 (hu) 2000-09-28
WO1998051787A2 (en) 1998-11-19
HUP0001931A3 (en) 2003-10-28
GB2338484B (en) 2001-11-07
GB9709421D0 (en) 1997-07-02
AU7225498A (en) 1998-12-08
GB2338484A (en) 1999-12-22
JP2001526539A (ja) 2001-12-18
NO995475L (no) 2000-01-07
ES2314990T3 (es) 2009-03-16
PL337007A1 (en) 2000-07-31
ZA983931B (en) 1998-11-10
AU734915B2 (en) 2001-06-28
NZ500014A (en) 2001-08-31
EP0979292A2 (en) 2000-02-16
CA2286875A1 (en) 1998-11-19
KR20010012441A (ko) 2001-02-15

Similar Documents

Publication Publication Date Title
US6339070B1 (en) Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
JP3786695B2 (ja) 修飾した抗原性免疾グロブリンによるt細胞の活性化
EP1098979B1 (en) Antibody with improved producibility
US10167328B2 (en) Methods for cancer therapy using mutant light molecules with increased affinity to receptors
US20030054003A1 (en) Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
CA2000913C (en) Family of high affinity antibodies for cancer treatment
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
US7638619B2 (en) Variable region gene of heavy/light chain of anti-human hepatoma monoclonal antibody HAb 18 and use thereof
Hardman et al. Generation of a recombinant mouse‐human chimaeric monoclonal antibody directed against human carcinoembryonic antigen
Yarnold et al. Chimerization of antitumor antibodies via homologous recombination conversion vectors
CZ396599A3 (cs) Genový konstrukt, který kóduje část zaměřující buňku a enzym aktivující proléčivo, pro použití jako léčivo
MXPA99010224A (en) Chemical compounds
US6953568B1 (en) Targeting of molecules to large vessel endothelium using EPCR
JP2004508035A (ja) エンドグリン特異的ポリペプチド、その製造及び使用
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도